1-8 of 8
Prahlad Ram
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer

Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4449.
https://doi.org/10.1158/1078-0432.CCR-21-2115
Published: 01 August 2021
View article titled, Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
Open the PDF for Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer in another window
Journal Articles

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression

Heather J. Dalton, Sunila Pradeep, Michael McGuire, Yared Hailemichael, Shaolin MA, Yasmin Lyons, Guillermo N. Armaiz-Pena, Rebecca A. Previs, Jean Marie Hansen, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Min Soon Cho, Sherry Y. Wu, Lingegowda S. Mangala, Nicholas B. Jennings, Wei Hu, Robert Langley, Hong Mu, Michael Andreeff, Menashe Bar-Eli, Willem Overwijk, Prahlad Ram, Gabriel Lopez-Berestein, Robert L. Coleman, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7034–7046.
https://doi.org/10.1158/1078-0432.CCR-17-0647
Published: 14 November 2017
View article titled, Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Open the PDF for Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression in another window
Includes: Supplementary data
Journal Articles

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer

Yu Kang, Archana S. Nagaraja, Guillermo N. Armaiz-Pena, Piotr L. Dorniak, Wei Hu, Rajesha Rupaimoole, Tao Liu, Kshipra M. Gharpure, Rebecca A. Previs, Jean M. Hansen, Cristian Rodriguez-Aguayo, Cristina Ivan, Prahlad Ram, Vasudha Sehgal, Gabriel Lopez-Berestein, Susan K. Lutgendorf, Steven W. Cole, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1713–1724.
https://doi.org/10.1158/1078-0432.CCR-15-1275
Published: 31 March 2016
View article titled, Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer
Open the PDF for Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer

Yunfei Wen, Whitney S. Graybill, Rebecca A. Previs, Wei Hu, Cristina Ivan, Lingegowda S. Mangala, Behrouz Zand, Alpa M. Nick, Nicholas B. Jennings, Heather J. Dalton, Vasudha Sehgal, Prahlad Ram, Ju-Seog Lee, Pablo E. Vivas-Mejia, Robert L. Coleman, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 448–459.
https://doi.org/10.1158/1078-0432.CCR-14-1578
Published: 14 January 2015
View article titled, Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
Open the PDF for Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Phospho proteomics and systems reconstruction of signaling networks to identify targets for therapy

Iadevaia Sergio, Melissa Muller, Prahlad Ram
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B46.
Published: 15 August 2014
View article titled, Phospho proteomics and systems reconstruction of signaling networks to identify targets for therapy
Journal Articles

Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks

Fabiana C. Morales, Sergio Iadevaia, Yiling Lu, Prahlad Ram, Gordon B. Mills, UT M.D.
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): B32.
https://doi.org/10.1158/DIAG-10-B32
Published: 15 August 2014
View article titled, Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks
Journal Articles

Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer

Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, Anil K. Sood
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2740–2750.
https://doi.org/10.1158/1078-0432.CCR-13-2507
Published: 14 May 2014
View article titled, Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
Open the PDF for Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)

Craig L. Slingluff, Jr, Gina R. Petroni, Kerrington R. Molhoek, David L. Brautigan, Kimberly A. Chianese-Bullock, Amber L. Shada, Mark E. Smolkin, Walter C. Olson, Alison Gaucher, Cheryl Murphy Chase, William W. Grosh, Geoffrey R. Weiss, Aubrey G. Wagenseller, Anthony J. Olszanski, Lainie Martin, Sofia M. Shea, Gulsun Erdag, Prahlad Ram, Jeffrey E. Gershenwald, Michael J. Weber
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3611–3620.
https://doi.org/10.1158/1078-0432.CCR-12-3919
Published: 30 June 2013
View article titled, Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Open the PDF for Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47) in another window
Includes: Supplementary data